Nestlé links with US human cell supplier to advance nutrition research

NIHS: “The cell products supplied by CDI include a variety of cell types that will benefit several areas of investigation at the Institute including Metabolic Health, Gastro-intestinal Health and Brain Health..."

Nestlé Institute of Health Sciences (NIHS) has inked a deal with a Wisconsin-based biotech firm that will keep it in supply of human brain and liver cells for nutrition testing purposes with a focus on drinks, smoothies and other products targeting diabetes and obesity.

NIHS will gain access to Cellular Dynamics International’s (CDI) iCell offerings that include cardiomyocytes, neurons, hepatocytes, and endothelial cells, “with numerous other cell types in development.”

The Swiss food giant was keen to highlight the fact the cells are derived from adult-sourced, “reprogrammed [from a] non-embryonic terminally differentiated cell type” which avoided, “the controversial and ethical issues surrounding embryonic stem cells whilst serving as excellent models of human cellular and tissue physiology from healthy and disease states.”

Bob Palay, CDI chief executive officer welcomed his firm's expansion into nutrition. "Our customers already benefit from a reliable supply of human [cells] and human differentiated cells for their biomedical research and drug discovery. This supply agreement with NIHS adds nutritional research as yet another field that will benefit from CDI's products and expertise."

NIHS and CDI have already worked together and presented some of the work at the International Society for Stem Cell Research (ISSCR) and the 11th Annual Meeting and at the EASD Islet Study Group (ISG) Annual Meeting.

NIHS added: “The cell products supplied by CDI include a variety of cell types that will benefit several areas of investigation at the Institute including Metabolic Health, Gastro-intestinal Health and Brain Health and will facilitate building the Institute’s platform for developing relevant cellular models of health and disease.”

Nestlé research investments

Based at the École Polytechnique Fédérale de Lausanne (EPFL), Switzerland, NIHS kicked into life at the end of 2012. Its stated mission is to provide a scientific rationale for targeted nutritional medical products to help manage health problems including diabetes, obesity and Alzheimer’s disease.

The launch of the NIHS is the latest in a line of research focused moves from Nestlé including the initial establishment of Nestlé Health Science in 2011, the centralisation of clinical research efforts at its Clinical Development Unit in 2012 , and the extension of research efforts at its Product Technology Centre in Konolfingen, Switzerland – which focuses on the development of infant formula, dairy products and medical nutrition.

Nestlé also opened a new Research & Development Centre in Manesar, India in 2012.

Last year Nestlé purchased medical foods specialist, Pamlab.

Related News

Producing attractive finger foods - rather than those that require cutlery - could encourage people with Alzheimer's disease to eat more, say researchers.

Finger foods may be best for people with Alzheimer's

Biomimicry looks at natural systems as a source of information first.

Concept of biomimicry could inform nutraceutical discovery, manufacture, expert says

“Yes we can find new natural molecules in these,” BRAIN says of even the most researched fruits and vegetables.

Germans unite on nutritive compound project

Nestlé defends plant patenting as 300,000 protest

Nestlé defends plant patenting as 300,000 protest

Nestlé sells Jenny Craig in North America, Oceania to PE firm

Nestlé sells Jenny Craig weight management business in North America and Oceania to PE firm

Nestlé research discovers 'distinct metabolic signature' for obesity

Nestlé research discovers 'distinct metabolic signature' for obesity

Nestlé plans to sell underperforming brands

Nestlé plans to sell underperforming brands

“These findings show that dietary lactoferrin supplementation improves gut comfort..."

Nestlé lodges patent for lactoferrin diarrhoea supplement

Nestlé said use of omega-3s from flaxseed was 'advantageous' because its more easily digestible

Nestlé files flax omega-3 cereal fortification patent

Nestlé finds way to add beta-alanine to energy bars without negative side-effects such as tingling, flushing and pins and needles

Nestlé files patent for tingle-free amino acid energy bars

Nestlé: “We use animals as part of our medical food research programme..."

Nestlé: ‘Our animal testing has nothing to do with superfoods or health claims’

Nestlé invests in medical nutrition

Nestlé invests in medical nutrition

Related Products

See more related products

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.